# Teligene

**Canonical:** https://apis.io/providers/teligene/  
**Website:** https://www.teligenebio.cn/en/  
**APIs profiled:** 0

Teligene (Suzhou Teligene Biotechnology Co., Ltd.) is a clinical-stage biopharmaceutical company founded in 2011 in Suzhou, China by Dr. Zhang Dawei, a former chief scientist at Amgen. The company focuses on the design, research and industrialization of innovative small-molecule targeted drugs for oncology, with a pipeline addressing lung cancer, breast cancer, and head and neck squamous cell carcinoma. Teligene US LLC is a wholly owned US subsidiary advancing these candidates through clinical development. It was surfaced as a portfolio company of idg-capital and added to the API Evangelist network for enrichment; as a drug-development biotech it publishes no public API, developer portal, or machine-readable API surface.

## Kin Score — 2.2 / 100 (minimal)

Scored 2026-08-20 under rubric 0.12.0. Trend: flat (+0.0 from 2.2).

| Facet | Score |
|---|---|
| Discoverability | 50.0 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 0.0 |
| Commercial Clarity | 0.0 |
| Access Clarity | 0.0 |

Regulatory layer — **Health**: 0.0 (matched via tags).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## Access

Unknown — onboarding: unknown, pricing: unknown, trial: no (confidence: low).

## Tags

Company, Healthcare, Biotechnology, Pharmaceuticals, Oncology, Drug Discovery

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/teligene/). Scores are computed from the provider's own public artifacts under a published rubric.